All In Biotech

Drug Trial Radar · NCT02864381

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Sep 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Sep 1, 2016

Primary completion

Nov 8, 2017

Study completion Aug 23, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Conditions

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • AndecaliximabDrug

    800 mg administered via IV infusion

  • NivolumabDrug

    3 mg/kg administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to 41 weeks

Locations

34 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Chicago, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Albury, New South Wales, Australia

  • Site not named

    Wahroonga, New South Wales, Australia

  • Site not named

    Douglas, Queensland, Australia

  • Site not named

    Hobart, Tasmania, Australia

  • Site not named

    La Louvière, Hainaut, Belgium

  • Site not named

    Ghent, Oost-Vlaanderen, Belgium

  • Site not named

    Leuven, Vlaams Brabant, Belgium

  • Site not named

    Brest, Finistère, France

  • Site not named

    Reims, Marne, France

  • Site not named

    Villejuif, Val-de-Marne, France

  • Site not named

    Budapest, Hungary

  • Site not named

    Debrecen, Hungary

  • Site not named

    Meldola, Forli-Cesena, Italy

  • Site not named

    Genova, Ligura, Italy

  • Site not named

    Milan, Lombardy, Italy

  • Site not named

    Pisa, Tuscany, Italy

  • Site not named

    Poznan, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Brzozów, Podkarpackie Voivodeship, Poland

  • Site not named

    Barcelona, Spain

  • Site not named

    Barcelona, Barcelona, Spain

  • Site not named

    Majadahonda, Madrid, Spain

  • Site not named

    Bristol, United Kingdom

  • Site not named

    Edgbaston, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Manchester, United Kingdom

  • Site not named

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.